Abstract
Introduction: VOYAGE 2, a Phase 3, randomized, double-blind, placebo/active comparator-controlled trial in patients with moderate-to-severe psoriasis (PsO), evaluated efficacy and safety of guselkumab (GUS; anti-interleukin-23). Results up to 5 years of continuous GUS treatment are presented.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
